Search

Your search keyword '"Pigozzi, Eva"' showing total 3 results
Start Over Author "Pigozzi, Eva" Topic ovarian cancer
3 results on '"Pigozzi, Eva"'

1. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.

Author

Farolfi, Alberto, Scarpi, Emanuela, Greco, Filippo, Bergamini, Alice, Longo, Lucia, Pignata, Sandro, Casanova, Claudia, Cormio, Gennaro, Bologna, Alessandra, Orditura, Michele, Zavallone, Laura, Attademo, Laura, Gallà, Valentina, Franzese, Elisena, Pigozzi, Eva, Loizzi, Vera, Giorda, Giorgio, Giardina, Donatella, Cioffi, Raffaella, and De Giorgi, Ugo

Subjects
OVARIAN cancer, CANCER prognosis, NEUTROPHILS, LYMPHOCYTES, IMMUNOLOGY of inflammation, PLATINUM, DISEASE progression, MULTIVARIATE analysis
Abstract

Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) are prognostic factors in epithelial ovarian cancer (EOC). Their predictive value for platinum-sensitivity and their role in recurrent EOC are unknown. A total of 375 EOC patients were retrospectively analyzed. The correlation between baseline NLR and SII, and platinum-free interval (PFI) according to first line bevacizumab treatment were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Subsequently NLR and SII calculated before second line treatment initiation were evaluated to identify a potential correlation with progression-free survival (PFS) and overall survival (OS) in platinum-sensitive and in platinum-resistant population. In multivariate analysis, NLR ≥ 3 is an independent predictive factor for PFI at 6 months in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004), not in bevacizumab treated patients. After having adjusted for ECOG performance status, histology, ascites, bevacizumab treatment at second line and BRCA status, NLR ≥ 3 and SII ≥ 730 are significantly associated with worse OS in platinum-sensitive (HR = 2.69, 95% CI 1.60–4.53, p = 0.002; HR = 2.11, 95% CI 1.29–3.43, p = 0.003, respectively), not in platinum-resistant EOC patients. Low NLR is an independent predictive factor for platinum-sensitivity in patients treated without bevacizumab. NLR and SII are prognostic factors in recurrent platinum-sensitive EOC patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

2. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study

Author

Raffaella Cioffi, Alessandra Bologna, Gennaro Cormio, Alice Bergamini, Vera Loizzi, Emanuela Scarpi, Alberto Farolfi, Michele Orditura, Sandro Pignata, Filippo Greco, Giorgio Giorda, Ugo De Giorgi, Lucia Longo, Claudia Casanova, Valentina Gallà, Donatella Giardina, Eva Pigozzi, L. Zavallone, Elisena Franzese, Laura Attademo, Farolfi, Alberto, Scarpi, Emanuela, Greco, Filippo, Bergamini, Alice, Longo, Lucia, Pignata, Sandro, Casanova, Claudia, Cormio, Gennaro, Bologna, Alessandra, Orditura, Michele, Zavallone, Laura, Attademo, Laura, Gallà, Valentina, Franzese, Elisena, Pigozzi, Eva, Loizzi, Vera, Giorda, Giorgio, Giardina, Donatella, Cioffi, Raffaella, and De Giorgi, Ugo

Subjects
Adult, Oncology, medicine.medical_specialty, Multivariate analysis, endocrine system diseases, Bevacizumab, Prognosi, Population, lcsh:Medicine, ECOG Performance Status, Carcinoma, Ovarian Epithelial, Logistic regression, Article, Young Adult, Antineoplastic Agents, Immunological, Ovarian cancer, Retrospective Studie, Internal medicine, Ascites, medicine, Humans, Epithelial ovarian cancer, lcsh:Science, education, Retrospective Studies, Aged, Ovarian Neoplasms, Aged, 80 and over, Inflammation, education.field_of_study, Multidisciplinary, business.industry, Ovarian Neoplasm, lcsh:R, fungi, Retrospective cohort study, Middle Aged, Prognosis, female genital diseases and pregnancy complications, lcsh:Q, Female, Neoplasm Recurrence, Local, medicine.symptom, business, Human, medicine.drug
Abstract

Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) are prognostic factors in epithelial ovarian cancer (EOC). Their predictive value for platinum-sensitivity and their role in recurrent EOC are unknown. A total of 375 EOC patients were retrospectively analyzed. The correlation between baseline NLR and SII, and platinum-free interval (PFI) according to first line bevacizumab treatment were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Subsequently NLR and SII calculated before second line treatment initiation were evaluated to identify a potential correlation with progression-free survival (PFS) and overall survival (OS) in platinum-sensitive and in platinum-resistant population. In multivariate analysis, NLR ≥ 3 is an independent predictive factor for PFI at 6 months in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004), not in bevacizumab treated patients. After having adjusted for ECOG performance status, histology, ascites, bevacizumab treatment at second line and BRCA status, NLR ≥ 3 and SII ≥ 730 are significantly associated with worse OS in platinum-sensitive (HR = 2.69, 95% CI 1.60–4.53, p = 0.002; HR = 2.11, 95% CI 1.29–3.43, p = 0.003, respectively), not in platinum-resistant EOC patients. Low NLR is an independent predictive factor for platinum-sensitivity in patients treated without bevacizumab. NLR and SII are prognostic factors in recurrent platinum-sensitive EOC patients.

Published
2020

3. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

Author

Lucia Longo, Jole Ventriglia, Sandro Pignata, Filippo Greco, Gennaro Cormio, Ugo De Giorgi, Alberto Farolfi, Vera Loizzi, Micaela Petrone, Michele Orditura, Eva Pigozzi, Giorgio Giorda, Valentina Gallà, Claudia Casanova, Raffaella Cioffi, Alessandra Bologna, Donatella Giardina, Emanuela Scarpi, Elisena Franzese, L. Zavallone, Farolfi, Alberto, Petrone, Micaela, Scarpi, Emanuela, Gallà, Valentina, Greco, Filippo, Casanova, Claudia, Longo, Lucia, Cormio, Gennaro, Orditura, Michele, Bologna, Alessandra, Zavallone, Laura, Ventriglia, Jole, Franzese, Elisena, Loizzi, Vera, Giardina, Donatella, Pigozzi, Eva, Cioffi, Raffaella, Pignata, Sandro, Giorda, Giorgio, and De Giorgi, Ugo

Subjects
Adult, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, medicine.medical_treatment, Population, Carcinoma, Ovarian Epithelial, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, Humans, Pharmacology (medical), Progression-free survival, Stage (cooking), education, Aged, Retrospective Studies, Aged, 80 and over, Inflammation, Ovarian Neoplasms, education.field_of_study, Chemotherapy, business.industry, Retrospective cohort study, Middle Aged, Prognosis, medicine.disease, Progression-Free Survival, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Ovarian cancer, business, medicine.drug
Abstract

The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. The MITO group conducted a multicenter, retrospective study (MITO 24) to investigate the role of inflammatory indexes as prognostic factors and predictors of treatment efficacy in FIGO stage III–IV EOC patients treated with first-line chemotherapy alone or in combination with bevacizumab. Of the 375 patients recruited, 301 received chemotherapy alone and 74 received chemotherapy with bevacizumab. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were evaluated to identify a potential correlation with PFS and OS in both the overall population and the two treatment arms. In the overall population, the PFS and OS were significantly longer in patients with low inflammatory indexes (p

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results